Real-World Evidence Confirms Oral Semaglutide's Metabolic Potency

While the global phase 3 PIONEER clinical program established the safety and efficacy of oral semaglutide, there remained a distinct clinical gap regarding how these findings translate into the routine care of the unique Indian phenotype, which is characterized by earlier disease onset and central adiposity. To address this, Prof. Debmalya Sanyal from the Department of Endocrinology at Ananda Clinic in Kolkata, along with a team of national experts, initiated the PIONEER REAL India study to evaluate the clinical impact and weight-loss potential of oral semaglutide in adults with type-2 diabetes (T2D) who were previously naïve to injectable glucose-lowering medications.

Therefore, the 34–44-week, multicenter, prospective, single-arm, non-interventional study monitored 388 participants across 29 primary and specialist care centers in India who initiated oral semaglutide at doses of 3 mg, 7 mg, or 14 mg as part of their routine physician-directed care. Utilizing a mixed model for repeated measurements (MMRM) to analyze the full analysis set (FAS) during the on-treatment observation period, researchers excluded individuals with mental incapacity or those who had used investigational drugs within the preceding thirty days to focus on the primary endpoint of absolute change in HbA1c alongside secondary endpoints such as percentage body weight change and the proportion of participants reaching a target HbA1c of less than 7%.

Key Clinical Findings of the Study Include:

• Significant Glycemic Improvement: The investigation shows that the treatment with oral semaglutide resulted in a significant reduction of HbA1c from 9.0% at baseline to 7.3% by the study's end.

• Substantial Weight Reduction: Participants achieved a notable mean body weight loss of -7.23 kg, dropping from 89.0 kg to 81.8 kg as confirmed by the study.

• Effective Target Achievement: The proportion of individuals reaching the HbA1c goal of less than 7% rose from 11.6% at baseline to 34.2%, as reported by the research.

• Enhanced Subgroup Performance: Patients with baseline HbA1c levels above 9% experienced a more pronounced -2.48%-point reduction compared to those starting with lower levels, as documented by the analysis.

• Manageable Tolerability Profile: Gastrointestinal (GI) disorders like nausea occurred in 12.1% of participants, yet no new safety signals were identified throughout the trial.

The results suggest that once-daily oral semaglutide is an effective real-world therapeutic option for Indian adults with T2D, demonstrated by the fact that 94.8% of participants achieved clinical success as defined by their healthcare providers (HCPs) and 70.1% maintained treatment adherence through to the study's conclusion. Furthermore, the data indicates that 58.7% of participants achieved a composite clinical endpoint of reducing their HbA1c by at least 1%-point while simultaneously losing 3% or more of their initial body weight.

Thus, the study concludes that clinicians may consider the early integration of oral semaglutide into treatment regimens to help patients achieve simultaneous glycemic and weight-loss goals in a real-world setting.

While the study's single-arm design and the potential for confounding by indication should be noted, further real-world research focused on the long-term cost-effectiveness of this medication in the Indian healthcare environment could provide additional valuable insights for sustainable diabetes management.

Reference

Sanyal D, Saboo B, Phatak SR, Kumar PKM, Basu D, Verma N, et al. Real-world usage of once-daily oral semaglutide in adults with type 2 diabetes: Findings from PIONEER REAL India. Indian J Endocr Metab 2025;29:523-30.